Yes, IT IS BREAKING HEALTH NEWS
June 5, 2022
It has been in all the news the past days:
“100% of Patients in study have cancer erased”
“Unheard-of”: Cancer drug in small trial shows full remission”
“Trial eliminateS cancer for 18 participants”
“A breakthrough in cancer cure”
The New York Memorial Sloan Kettering Cancer Center treated a small number of patients with locally advanced rectal cancer with Dostarlimab, an immunotherapy medicine.
All the patients who completed 6 months of treatment had complete tumor resolution on FDG-PET
The results were written in the New England Journal of Medicine as “PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer”. A link to the actual medical article follows below.
Under RESULTS: Patients, Tumor Characteristics, Efficacy, Safety (adverse reactions), and Biomarkers of Longitudinal Response.
“A total of 16 patients have been enrolled and treated (Table 1). Of these patients, 12 have been enrolled for longer than 6 months and have completed the nine planned cycles (6 months) of dostarlimab. The median follow-up time from study enrollment to the clinical data cutoff for the 12 patients is 12 months (range, 6 to 25). The remaining 4 patients have received at least one dose of dostarlimab and continue to receive treatment. The median age of all the enrolled patients is 54 years (range, 26 to 78), and 62% are women. All 16 patients met the eligibility criteria, and no patients have withdrawn from the study. Of the 16 patients, 15 have clinical stage III disease, and 1 has clinical stage II disease. The most common presenting symptoms were rectal bleeding (in 88% of the patients), constipation (in 31%), and abdominal pain (in 25%).”
To view the New England Journal of Medicine’s actual report, click here.